Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285825 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
A Phase 2 study of Cytopenia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06285825: Recruiting Phase 2 study of Cytopenia, sponsored by M.D. Anderson Cancer Center.
NCT06285825 is a Phase 2 study of Cytopenia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 376-participant average among 11 other Cytopenia trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06285825, a Phase 2 study of Cytopenia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Emapalumab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 2 |
What NCT06285825 shows while recruiting
NCT06285825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 376-participant average among 11 other Cytopenia trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Emapalumab is the first listed.
NCT06285825 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06285825 about?
NCT06285825 is a clinical study titled "A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia". To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.
What is the current status of trial NCT06285825?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2024-07-05. Estimated completion is 2028-08-22.
What conditions does trial NCT06285825 study?
This clinical trial studies the following conditions: Cytopenia.
What interventions are being tested in trial NCT06285825?
The interventions under investigation include: Emapalumab (DRUG).
Who is sponsoring clinical trial NCT06285825?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06285825 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06285825's enrollment target sits among peer trials
32 10th of 11 higher than 2 of 11 other Cytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI